Show simple item record

dc.contributor.authorVaux, DL
dc.date.accessioned2020-12-10T00:48:10Z
dc.date.available2020-12-10T00:48:10Z
dc.date.issued2009-10-29
dc.identifier.citationVaux, D. L. (2009). Inhibitor of Apoptosis (IAP) proteins as drug targets for the treatment of cancer.. F1000 Biol Rep, 1, pp.79-. https://doi.org/10.3410/B1-79.
dc.identifier.issn1757-594X
dc.identifier.urihttp://hdl.handle.net/11343/253577
dc.description.abstractThree companies, Genentech, Aegera Therapeutics/Human Genome Sciences, and Novartis, have commenced phase 1 clinical trials of inhibitor of apoptosis (IAP) antagonist 'Smac mimetic' compounds for the treatment of cancer. These trials represent the culmination of a line of research that commenced with analysis of how insect viruses stop host cells from killing themselves and led to the discovery of a family of proteins that regulate development in insects and signalling by tumour necrosis factor superfamily members in mammals, which prompted development of drugs that mimic natural IAP-binding proteins to promote cell death.
dc.languageeng
dc.publisherFaculty Opinions Ltd
dc.rights.urihttps://creativecommons.org/licenses/by-nc/4.0
dc.titleInhibitor of Apoptosis (IAP) proteins as drug targets for the treatment of cancer.
dc.typeJournal Article
dc.identifier.doi10.3410/B1-79
melbourne.affiliation.departmentMedical Biology (W.E.H.I.)
melbourne.source.titleF1000 biology reports
melbourne.source.volume1
melbourne.source.pages79-
dc.rights.licenseCC BY-NC
melbourne.elementsid1321780
melbourne.openaccess.pmchttp://www.ncbi.nlm.nih.gov/pmc/articles/PMC2948278
melbourne.contributor.authorVaux, David
dc.identifier.eissn1757-594X
melbourne.accessrightsOpen Access


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record